Critique of FDA’s latest SSRI Data Analysis
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
PRESS BRIEFING: Critique of FDA Report: “Clinical review relationship between antidepressant drugs and suicidality in adults, 2006” http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4272b1-index.htm
Two Press Briefings are planned to demonstrate the multiple flaws in FDA's methodology and to provide credible science-based information.
"the first-ever randomized, placebo-controlled trial for the alleviation of post-traumatic stress disorder (PTSD)" reports: "we found that it really offered patients no benefits of any symptoms." [1]
U.S. State Attorneys General should investigate the fraudulent marketing of the atypical neuroleptic drugs-and FDA's role in helping conceal the truth.
An eye opening article by Jeanne Lenzer, “NIH Secrets,” in The New Republic (below), should make the new Congress sit up and take notice!
This is an addendum to yesterday's Infomail in which we disseminated disinformation issued by the U.S. Center for Disease Control (CDC). www.ahrp.org/cms/content/view/396/80
Steven Fiorello, former Chief Pharmacist for the State of Pennsylvania, was arraigned on on Tuesday, November 21, 2006, on Felony and Misdemeanor charges related to his accepting money from drug companies whose drugs he put on the state Formulary.
Today's news report circulated by the media about the negative findings of a much touted, but uncontrolled observational study of depression (STAR*D) promotes the business interests of SSRI antidepressant drug manufacturers.
"Some politicians, public health officials, mental health activists and pharmaceutical companies have worked to establish mental-health screening programs in schools and the community….Researchers and clinicians, meanwhile, say they are far from having developed accurate predictors of a child developing depression. The younger the child, the murkier the crystal ball."
NYSOMH Issues Alerts, Guidelines re Antidepressant Use in Children, Teens Wed, 29 Dec 2004 The NYS Office of Mental Health has issued letters and an advisory to state mental health providers “explaining” FDA’s warning and the use of antidepressants in children. As you will note, OMH downplays the meaning of…
FDA Alert: Effexor warnings added for neonatal adverse effects and suicidality risk Tue, 29 Jun 2004 On June 28, the FDA and Wyeth issued a new MedWatch drug Alert to healthcare professionals: “Neonates exposed to Effexor, other SNRIs (Serotonin and Norepinephrine Reuptake Inhibitors), or SSRIs (Selective Serotonin Reuptake Inhibitors), late…
Op Ed: Psychiatry on the Ropes–WP / Evidence-based Psychiatry– Multi-Discipline Conference_ NYC Mon, 4 Oct 2004 An Op Ed article in The Washington Post by Shannon Brownlee (below) nails the elite procurers of psychotropic drugs who have long denied the ominous signals of drug-induced harm: “You’d think the psychiatric research…